Competitor Analysis: HPV Vaccines

Date: May 23, 2010
Pages: 18
US$ 180.00
License [?]:
Publisher: La Merie Publishing
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)

Download PDF Leaflet

Competitor Analysis: HPV Vaccines
Product description

The present Competitive Intelligence Report about HPV Vaccines provides a competitor evaluation in the field of investigational vaccines against infection with the human papilloma virus (HPV) for prophylaxis of genital and anal warts and of cervical precancer as of May 2010. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

Genital human papilloma virus is one of the most common sexually transmitted infections (STI). Two vaccines are commercially available to protect females against the types of HPV that cause most cervical cancers. One of these vaccines also protects against most genital warts. Both vaccines are recommended for 11 and 12 year-old girls, and for females 13 through 26 years old, who did not get any or all of the three recommended doses when they were younger. The approved vaccines protect against two or four, respectively, most common types of HPV. A number of further vaccine candidates are in development utilizing various technologies for expression of the antigens and various adjuvants. Some vaccines also are directed against more or different types of HPV or are designed as therapeutic vaccines by induction of T cell immunity.

The report includes a compilation of currently active projects in development of vaccines targeting various types of human papilloma virus for prophylaxis of genitoanal warts and cervical precancer (cervical intraepithelial neoplasia or CIN). In addition, the report lists company-specific R&D pipelines of HPC Vaccines. Competitor projects are listed in a tabular format providing information on:

  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.
  • HPV Vaccines
  • Corporate HPV Vaccines R&D Pipelines
  • About La Merie
About Competitor Analysis Series

The Competitor Analysis Series delivers NO-FRILLS , but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced. Competitor analysis reports can be purchased as individual products or obtained by subscribing to R&D Pipeline News. R&D Pipeline News is published weekly 50-times a year and each issue contains at least two competitor evaluations.

Skip to top

Competitor Analysis: Malaria Vaccines & Therapeutics US$ 390.00 Aug, 2012 · 64 pages
Competitor Analysis: Anthrax Vaccines & Therapeutics US$ 257.00 Jun, 2013 · 32 pages
Competitor Analysis Influenza Vaccines US$ 718.00 May, 2011 · 123 pages
Competitor Analysis: Hepatitis Vaccines US$ 498.00 Jun, 2011 · 96 pages
Competitor Analysis: Cancer Vaccines US$ 1,112.00 Mar, 2014 · 179 pages

Ask Your Question

Competitor Analysis: HPV Vaccines
Company name*:
Contact person*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: